GHRH and benign prostatic hyperplasia: Analyses indicate that treatment with GHRH antagonists suppresses the expression of pro-inflammatory cytokines in benign prostatic hyperplasia (BPH).[42, 43] These results also support the hypothesis that GHRH antagonists will suppress the expression of the inflammatory cytokines associated with breast cancer.